PTEN突变对子宫内膜癌患者预后和药物敏感性的影响

Effect of PTEN Mutation in the Prognosis and Drug Sensitivity in Endometrial Cancer

目的分析子宫内膜癌组织中PTEN突变及其对子宫内膜癌患者预后的影响,寻找对PTEN突变子宫内膜癌敏感的药物。方法利用cBioPortal数据库研究子宫内膜癌组织中PTEN突变情况及其对子宫内膜癌患者预后的影响。利用GDSC数据库寻找对PTEN突变子宫内膜癌敏感的药物。结果PTEN在子宫内膜癌组织中的突变频率为65.2%。与野生型相比,PTEN突变的子宫内膜癌患者总生存期和无进展生存期均延长。PTEN突变型和的野生型子宫内膜癌细胞对顺铂(P=0.055)和紫杉醇(P=0.09)的IC50无明显差异。PTEN突变型子宫内膜癌细胞对AKT激酶抑制剂Afuresertib(P=0.047)的敏感性增强。结论PTEN突变能够延长子宫内膜癌患者总生存期和无进展生存期,AKT激酶抑制剂Afuresertib有望成为PTEN突变子宫内膜癌患者的精准治疗药物。

OBJECTIVE To analyze the effect of PTEN mutation in the prognosis and drug sensitivity in Endometrial cancer,to search drugs that sensitive to Endometrial cancer patients with PTEN mutation.METHODS We use cBioPortal database to analyze the effect of PTEN mutation in the prognosis of Endometrial cancer,GDSC dataset was used to identified the drugs that sensitive to cell lines with PTEN mutation.RESULTS Our results showed that PTEN mutation was carried in 65.2% of Endometrial cancer patients.Prognosis analysis showed that there were favorable overall survival and progression free survival in Endometrial cancer patients with PTEN mutation.Moreover,it was more sensitive to AKT inhibitor-Afuresertib-on Endometrial cancer cell lines with PTEN mutation than that with wild type.CONCLUSION There were favorable overall survival and progression free survival in Endometrial cancer patients with PTEN mutation,it is more sensitive to AKT inhibitor-Afuresertib-on Endometrial cancer cell lines with PTEN mutation than that with wild type.These results provide a potential target and therapeutic strategies for patients with PTEN mutation.